This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Attention Sarepta Therapeutics, Inc. Investors: Sarepta Misled Investors According To A Recently Filed Class Action

Stocks in this article: SRPT

SAN DIEGO and CAMBRIDGE, Mass., Feb. 4, 2014 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of Massachusetts.  The complaint alleges that the company and certain of its officers violated the Securities and Exchange Act of 1934 between July 24, 2013 and November 12, 2013 (the "Class Period").  Sarepta is a biopharmaceutical company that develops RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is eteplirsen, which is in Phase IIb clinical development for the treatment of individuals with Duchenne muscular dystrophy.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO)

Sarepta Is Accused of Misstating the Significance of Eteplirsen Data Set

According to the complaint, Sarepta shares initially fell $3.26 per share, or 7.8%, to close at $38.63 per share on October 30, 2013, following the publication of reports challenging the significance of Sarepta's Phase IIb eteplirsen study data set.  Then, Sarepta shares fell an additional $23.40 per share, or 64%, to close at $13.16 on November 12, 2013, following the company's announcement that the Food and Drug Administration informed Sarepta that it considered its New Drug Application ("NDA") filing for  eteplirsen to be premature. 

According to the complaint, Sarepta misled investors by making materially false and misleading statements regarding the significance of its eteplirsen Phase IIb study data set and the likelihood of the FDA accepting the company's NDA for eteplirsen for review based on that data set.  As a result, Sarepta's common stock traded at artificially high prices throughout the class period.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,399.67 +19.26 0.12%
S&P 500 1,904.01 +17.25 0.91%
NASDAQ 4,316.0740 +57.6360 1.35%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs